WHO warns against dengue vac­cine risks

BioSpectrum (Asia) - - Who News -

Fresh con­cerns about the ef­fi­cacy of the world’s first ever Dengue vac­cine has come to light as the World Health Or­gan­i­sa­tion (WHO) noted that there is an ur­gent need to de­scribe the po­ten­tial risks of the vac­cine.

There­fore, WHO has ad­vised the coun­tries plan­ning to use the vac­cine to screen the pop­u­la­tion be­fore vac­ci­na­tion. It has strictly di­rected the coun­tries to vac­ci­nate only seropos­i­tive (tested pos­i­tive for dengue) in­di­vid­u­als.

Deng­vaxia (CYD-TDV), the vac­cine in ques­tion is pro­duced by the Phar­ma­ceu­ti­cal giant Sanofi Pas­teur. The Strate­gic Ad­vi­sory Group of Ex­perts (SAGE) for­mu­lated by WHO is ex­am­in­ing the con­cerns caused by the vac­cine.

SAGE has also looked at the pop­u­la­tion sero­preva­lence cri­te­ria (per­cent­age of pop­u­la­tion af­fected by dengue) to en­sure that only those af­fected by dengue get the jab.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.